The FDA found problems at three Merck KGaA API and drug manufacturing facilities along a single supply chain in Europe last summer from which ingredients were fed to a plant in Germany. It is unusual for the FDA to inspect different plants along the supply chain simultaneously, Pharmalot notes, and the connected inspections came as the agency was still feeling the heat from the Heparin scandal. FDA warning | Story
Editor's Note: This story had an incorrect stock symbol for Merck KGaA. The story has been updated and corrected.